These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 31673703)

  • 1. Glucagon-Receptor Signaling Reverses Hepatic Steatosis Independent of Leptin Receptor Expression.
    Nason SR; Kim T; Antipenko JP; Finan B; DiMarchi R; Hunter CS; Habegger KM
    Endocrinology; 2020 Jan; 161(1):. PubMed ID: 31673703
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glucagon Receptor Signaling Regulates Energy Metabolism via Hepatic Farnesoid X Receptor and Fibroblast Growth Factor 21.
    Kim T; Nason S; Holleman C; Pepin M; Wilson L; Berryhill TF; Wende AR; Steele C; Young ME; Barnes S; Drucker DJ; Finan B; DiMarchi R; Perez-Tilve D; Tschöp M; Habegger KM
    Diabetes; 2018 Sep; 67(9):1773-1782. PubMed ID: 29925501
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glucagon receptor signaling regulates weight loss via central KLB receptor complexes.
    Nason SR; Antipenko J; Presedo N; Cunningham SE; Pierre TH; Kim T; Paul JR; Holleman C; Young ME; Gamble KL; Finan B; DiMarchi R; Hunter CS; Kharitonenkov A; Habegger KM
    JCI Insight; 2021 Feb; 6(4):. PubMed ID: 33411693
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chronic treatment with glucagon-like peptide-1 and glucagon receptor co-agonist causes weight loss-independent improvements in hepatic steatosis in mice with diet-induced obesity.
    McGlone ER; Hope DCD; Davies I; Dore M; Goldin R; Jones B; Liu Z; Li JV; Vorkas PA; Khoo B; Carling D; Minnion J; Bloom SR; Tan TM
    Biomed Pharmacother; 2024 Jul; 176():116888. PubMed ID: 38861859
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of long acting GLP1R/GCGR agonist in a DIO and biopsy-confirmed mouse model of NASH suggest a beneficial role of GLP-1/glucagon agonism in NASH patients.
    Monfeuga T; Norlin J; Bugge A; Gaalsgaard ED; Prada-Medina CA; Latta M; Veidal SS; Petersen PS; Feigh M; Holst D
    Mol Metab; 2024 Jan; 79():101850. PubMed ID: 38065435
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glucagon receptor signaling at white adipose tissue does not regulate lipolysis.
    Vasileva A; Marx T; Beaudry JL; Stern JH
    Am J Physiol Endocrinol Metab; 2022 Oct; 323(4):E389-E401. PubMed ID: 36002172
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glucagon-like peptide 1/glucagon receptor dual agonism reverses obesity in mice.
    Pocai A; Carrington PE; Adams JR; Wright M; Eiermann G; Zhu L; Du X; Petrov A; Lassman ME; Jiang G; Liu F; Miller C; Tota LM; Zhou G; Zhang X; Sountis MM; Santoprete A; Capito' E; Chicchi GG; Thornberry N; Bianchi E; Pessi A; Marsh DJ; SinhaRoy R
    Diabetes; 2009 Oct; 58(10):2258-66. PubMed ID: 19602537
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD9 Counteracts Liver Steatosis and Mediates GCGR Agonist Hepatic Effects.
    Zheng Y; Wang Y; Xiong X; Zhang L; Zhu J; Huang B; Liu X; Liu J; Zhu Z; Yang G; Qu H; Zheng H
    Adv Sci (Weinh); 2024 Aug; 11(29):e2400819. PubMed ID: 38837628
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chronic IL-6 Administration Desensitizes IL-6 Response in Liver, Causes Hyperleptinemia and Aggravates Steatosis in Diet-Induced-Obese Mice.
    Gavito AL; Bautista D; Suarez J; Badran S; Arco R; Pavón FJ; Serrano A; Rivera P; Decara J; Cuesta AL; Rodríguez-de-Fonseca F; Baixeras E
    PLoS One; 2016; 11(6):e0157956. PubMed ID: 27333268
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The brown adipose tissue glucagon receptor is functional but not essential for control of energy homeostasis in mice.
    Beaudry JL; Kaur KD; Varin EM; Baggio LL; Cao X; Mulvihill EE; Stern JH; Campbell JE; Scherer PE; Drucker DJ
    Mol Metab; 2019 Apr; 22():37-48. PubMed ID: 30772257
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Disrupted Leptin Signaling in the Lateral Hypothalamus and Ventral Premammillary Nucleus Alters Insulin and Glucagon Secretion and Protects Against Diet-Induced Obesity.
    Denroche HC; Glavas MM; Tudurí E; Karunakaran S; Quong WL; Philippe M; Britton HM; Clee SM; Kieffer TJ
    Endocrinology; 2016 Jul; 157(7):2671-85. PubMed ID: 27183315
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduced adiponectin signaling due to weight gain results in nonalcoholic steatohepatitis through impaired mitochondrial biogenesis.
    Handa P; Maliken BD; Nelson JE; Morgan-Stevenson V; Messner DJ; Dhillon BK; Klintworth HM; Beauchamp M; Yeh MM; Elfers CT; Roth CL; Kowdley KV
    Hepatology; 2014 Jul; 60(1):133-45. PubMed ID: 24464605
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatic leptin receptor expression can partially compensate for IL-6Rα deficiency in DEN-induced hepatocellular carcinoma.
    Mittenbühler MJ; Sprenger HG; Gruber S; Wunderlich CM; Kern L; Brüning JC; Wunderlich FT
    Mol Metab; 2018 Nov; 17():122-133. PubMed ID: 30224299
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatic glucagon action is essential for exercise-induced reversal of mouse fatty liver.
    Berglund ED; Lustig DG; Baheza RA; Hasenour CM; Lee-Young RS; Donahue EP; Lynes SE; Swift LL; Charron MJ; Damon BM; Wasserman DH
    Diabetes; 2011 Nov; 60(11):2720-9. PubMed ID: 21885872
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Methionine restriction prevents the progression of hepatic steatosis in leptin-deficient obese mice.
    Malloy VL; Perrone CE; Mattocks DA; Ables GP; Caliendo NS; Orentreich DS; Orentreich N
    Metabolism; 2013 Nov; 62(11):1651-61. PubMed ID: 23928105
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CB
    Drori A; Gammal A; Azar S; Hinden L; Hadar R; Wesley D; Nemirovski A; Szanda G; Salton M; Tirosh B; Tam J
    Elife; 2020 Nov; 9():. PubMed ID: 33210603
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glucagon receptor antagonism impairs and glucagon receptor agonism enhances triglycerides metabolism in mice.
    Galsgaard KD; Elmelund E; Johansen CD; Bomholt AB; Kizilkaya HS; Ceutz F; Hunt JE; Kissow H; Winther-Sørensen M; Sørensen CM; Kruse T; Lau JF; Rosenkilde MM; Ørskov C; Christoffersen C; Holst JJ; Wewer Albrechtsen NJ
    Mol Metab; 2022 Dec; 66():101639. PubMed ID: 36400402
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metformin increases hepatic leptin receptor and decreases steatosis in mice.
    Tang X; Li J; Xiang W; Cui Y; Xie B; Wang X; Xu Z; Gan L
    J Endocrinol; 2016 Aug; 230(2):227-37. PubMed ID: 27288055
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glucagon-like peptide-1 receptor activation stimulates hepatic lipid oxidation and restores hepatic signalling alteration induced by a high-fat diet in nonalcoholic steatohepatitis.
    Svegliati-Baroni G; Saccomanno S; Rychlicki C; Agostinelli L; De Minicis S; Candelaresi C; Faraci G; Pacetti D; Vivarelli M; Nicolini D; Garelli P; Casini A; Manco M; Mingrone G; Risaliti A; Frega GN; Benedetti A; Gastaldelli A
    Liver Int; 2011 Oct; 31(9):1285-97. PubMed ID: 21745271
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glucagon-like peptide-1 receptor agonism improves metabolic, biochemical, and histopathological indices of nonalcoholic steatohepatitis in mice.
    Trevaskis JL; Griffin PS; Wittmer C; Neuschwander-Tetri BA; Brunt EM; Dolman CS; Erickson MR; Napora J; Parkes DG; Roth JD
    Am J Physiol Gastrointest Liver Physiol; 2012 Apr; 302(8):G762-72. PubMed ID: 22268099
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.